1. Home
  2. Directory
  3. Maine
  4. York
  5. Specialist
  6. NPI Profile
  7. Prescriptions 1891713632

DR. MARILYN ANGELA MCLAUGHLIN-MURRAY M.D.
Prescription History 1891713632
Specialist in York, ME


Quality Rating: 98.06 out of 100 score

NPI Status: Active since July 18, 2006

Contact Information

15 HOSPITAL DRIVE
YORK, ME
ZIP 03909
Phone: (207) 351-3777
Fax: (207) 351-3788

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MARILYN ANGELA MCLAUGHLIN-MURRAY M.D., an active Specialist specialist practicing in York, ME. Our medical registry currently tracks 7 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 215 documented patient claims. Among these therapy options, the most frequently utilized medication is Letrozole, which accounts for 52 claims alone.

Medication Index

Abiraterone Acetate

Generic Formulation: Abiraterone AcetateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
ME State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills49.6
Peer Average Days Supply1,485
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 56.3% less volume than the regional standard for practitioners inside ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $87,642.36 across this reporting matrix range.

Provider Avg Cost Per Claim

$4,173.45

State Avg Cost Per Claim

$3,945.99

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An androstene derivative that inhibits STEROID 17-ALPHA-HYDROXYLASE and is used as an ANTINEOPLASTIC AGENT in the treatment of metastatic castration-resistant PROSTATE CANCER.

Therapeutic Applications

This medication is used to treat prostate cancer. Abiraterone belongs to a class of drugs known as anti-androgens (anti-testosterone). Testosterone, a natural hormone, helps prostate cancer to grow and spread. Abiraterone works by blocking the production of testosterone, thereby slowing the growth and spread of prostate cancer. This medication should not be given to women or children.

Anastrozole

Generic Formulation: AnastrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 48
30-Day Fills 139.4
Days Supply 4,182
ME State Average Benchmarks
Peer Average Claims57.0
Peer Average 30-Day Fills142.5
Peer Average Days Supply4,248
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,525.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.78

State Avg Cost Per Claim

$32.61

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A nitrile and triazole derivative that acts as a selective nonsteroidal aromatase inhibitor. It is used in the treatment of ESTROGEN NUCLEAR RECEPTOR-positive breast cancer in postmenopausal women.

Therapeutic Applications

Anastrozole is used to treat breast cancer in women after menopause. Some breast cancers are made to grow faster by a natural hormone called estrogen. Anastrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Imbruvica

Generic Formulation: IbrutinibSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 37
30-Day Fills 37.0
Days Supply 1,054
ME State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.4
Peer Average Days Supply716
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 54.2% higher than the standard regional baseline profile for ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $526,583.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,231.99

State Avg Cost Per Claim

$15,871.48

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain cancers (such as mantle cell or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, Waldenstrom's macroglobulinemia). Ibrutinib belongs to a class of drugs known as kinase inhibitors. It works by slowing or stopping the growth of cancer cells. Ibrutinib is also used to treat a certain problem that may occur after a stem cell transplant (chronic graft versus host disease). It works by weakening your body's defense system (immune system).

Lenalidomide

Generic Formulation: LenalidomideSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 13
30-Day Fills 13.0
Days Supply 364
ME State Average Benchmarks
Peer Average Claims29.0
Peer Average 30-Day Fills29.0
Peer Average Days Supply812
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 55.2% less volume than the regional standard for practitioners inside ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $199,474.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$15,344.18

State Avg Cost Per Claim

$12,779.78

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phthalimide and piperidone derivative that has immunomodulatory and antiangiogenic properties. It is used for the treatment of transfusion-dependent anemia in MYELODYSPLASTIC SYNDROMES, and for the treatment of MULTIPLE MYELOMA, and relapsed or refractory MANTLE CELL LYMPHOMA.

Therapeutic Applications

Lenalidomide is used to treat various types of cancers. It works by slowing or stopping the growth of cancer cells. It is also used to treat anemia in patients with certain blood/bone marrow disorders (myelodysplastic syndromes-MDS). Lenalidomide may lessen the need for blood transfusions. Lenalidomide is not recommended for the treatment of a certain type of cancer (chronic lymphocytic leukemia) because of the increased risk of serious heart-related side effects and death. If you have this type of cancer, talk to your doctor about the risks of using this medication.

Letrozole

Generic Formulation: LetrozoleSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 52
30-Day Fills 139.7
Days Supply 4,190
ME State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills125.5
Peer Average Days Supply3,757
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,652.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$31.78

State Avg Cost Per Claim

$38.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A triazole and benzonitrile derivative that is a selective non-steroidal aromatase inhibitor, similar to ANASTROZOLE. It is used in the treatment of metastatic or locally advanced breast cancer in postmenopausal women.

Therapeutic Applications

This medication is used to treat certain types of breast cancer (such as hormone-receptor-positive breast cancer) in women after menopause. Letrozole is also used to help prevent the cancer from returning. Some breast cancers are made to grow faster by a natural hormone called estrogen. Letrozole decreases the amount of estrogen the body makes and helps to slow or reverse the growth of these breast cancers.

Prednisone

Generic Formulation: PrednisoneSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 33
30-Day Fills 43.0
Days Supply 1,096
ME State Average Benchmarks
Peer Average Claims40.0
Peer Average 30-Day Fills51.0
Peer Average Days Supply925
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $144.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$4.37

State Avg Cost Per Claim

$6.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Tamoxifen Citrate

Generic Formulation: Tamoxifen CitrateSpecialty: Medical Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 33.0
Days Supply 990
ME State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills88.6
Peer Average Days Supply2,651
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 68.6% less volume than the regional standard for practitioners inside ME. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $297.70 across this reporting matrix range.

Provider Avg Cost Per Claim

$27.06

State Avg Cost Per Claim

$43.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.

Therapeutic Applications

Tamoxifen is used to treat breast cancer. It is also used to reduce the chances of breast cancer in high-risk patients. This medication can block the growth of breast cancer. It works by interfering with the effects of estrogen in the breast tissue.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MARILYN ANGELA MCLAUGHLIN-MURRAY M.D. provides transparency into local medical care patterns within York, ME.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Specialist** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.